Early detection potential Mirxes flagship GASTROClear enables early gastric cancer detection with high sensitivity at Stage I-II, indicating strong upsell opportunities for companion tests in lung, thyroid, colorectal, breast, liver, and ovarian cancer early-detection portfolios to HCPs and diagnostic networks.

Geographic expansion Singapore-based hub with operations in USA, Japan, and China, plus global sales networks, presents cross-border sales opportunities with regional distributors, hospital systems, and private clinics seeking validated molecular blood tests for cancer screening in Asia-Pacific and beyond.

IPO momentum Recent Hong Kong IPO and multi-million financing raise Mirxes’ visibility and funding runway, creating avenues to secure larger pharma/biotech partnerships, co-development deals, and expanded marketing agreements with payers and diagnostics distributors.

At-home screening Launch of FITRapid and HELICORapid in Thailand signals demand for consumer-accessible diagnostics; explore direct-to-consumer channels, employer health programs, and regional regulatory approvals to broaden distribution and drive recurring revenue through at-home testing kits.

Clinical and research partnerships Origins from A*STAR with ID3EAL platform and breadth of biomarker discovery capabilities position Mirxes for strategic collaborations with hospitals, academic centers, and pharma for multi-cancer early detection programs and precision oncology insights.